Researchers in a groundbreaking neuroimaging study have discovered that individuals with depression exhibit significantly higher …
COAST GUARD VETERAN WALKING ACROSS AMERICA TO RAISE AWARENESS FOR MENTAL HEALTH
The Coast Guard Foundation, a non-profit organization committed to strengthening the Coast Guard community and …
Manasthali gives a new lease of life to a young man affected by Schizophrenia
Manasthali, a renowned mental health organization dedicated to offering innovative and compassionate treatment, has revitalised …
Acharya Prashant Engages with IIT Students on Mental Health and Spiritual Well-being
Acharya Prashant, founder of PrashantAdvait Foundation and former civil service officer, interacted with IIT students …
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its …
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products …
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that it has …
Family Care Center Expands Mental Health Support with New Nashville West End Clinic
Family Care Center, one of the nation’s premier mental health providers, is celebrating the opening …
Clinical trial on Ambio Life Sciences’ ibogaine treatment for Navy SEALs with traumatic brain injury published in Nature Medicine
Today, Nature Medicine published the results of a clinical trial, in which 30 former Navy SEALs were …
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)
Alkermes plc (Nasdaq: ALKS) today announced topline results from a phase 3, open-label extension study assessing the …
